AccuLine was founded with the vision to save the lives of millions of people worldwide, by preventing the next heart attack. AccuLine is developing CORA - a fast, non-invasive, inexpensive, and user-friendly examination for the early detection of coronary artery disease (CAD), aiming to replace the inaccurate ECG stress test exams. CORA’s technology is based on two new bio signals discovered by AccuLine in the electrical activity of the heart that correlate with CAD, as well as on advanced signal processing algorithms. AccuLine received a grant from the Israeli Innovation Authority and among our shareholders are eHealth Ventures, Maccabi Healthcare Services and Mayo Clinic.